Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE versus FLOVENT DISKUS 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE versus FLOVENT DISKUS 50.
DEXAMETHASONE vs FLOVENT DISKUS 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
None Documented
None Documented
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
Category D/X
Category C
Corticosteroid
Corticosteroid